€420M
Aggregate value of opportunities reviewed annually
<10
Investments per year, on average
2.4×
Indicative MOIC across realised positions (anonymized)
6
Listed-corporate exits in the partners' collective history
Selected positions — anonymized
2024
Orthobiology · Sweden
Series B participation. FDA Breakthrough Device Designation secured prior to entry.
2024
B2B SaaS · DACH
Series A lead. Co-invest from European institutional LP.
2023
Residential · Munich-Süd
Off-market acquisition below replacement cost.
2023
Applied AI · Nordics
Pre-Series A. Founders from previously-acquired listed peer.
2022
Green-tech · DE
Bridge to strategic. Realised within 18 months at 3.1× MOIC.